1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)" is currently closed and not accepting applications.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI).
This Notice of Funding Opportunity solicits SBIR grant applications from small business concerns to support later-stage research and development (Phase IIB) for projects previously funded under SBIR or STTR Phase II awards from any Federal agency. The goal is to bridge the funding gap between Phase II and commercialization for cancer-relevant technologies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) | Research Funding National Institutes of Health SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.
The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.
Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period.
Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required. Letter of Intent Due Date: July 21, 2024 Renewal / Resubmission / Revision Application Due Date(s): August 21, 2024 RFA-CA-24-022 Expiration Date August 22, 2024 Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Phase IIB projects, that are covered by NCI SBIR budget waiver topics ( https://seed. nih. gov/sites/default/files/HHS_Topics_for_Budget_Waivers.
pdf ), may request budgets up to $2,250,000 total costs for any single year. The combined budget requested for the entire project period must not exceed $4,500,000 total costs. For Phase IIB projects that do not fall under a waiver topic, budgets must be submitted in accordance with participating IC-specific budget limitations described in the current SBIR/STTR Program Descriptions and Research Topics of the NIH, CDC and FDA.
Applicants are strongly encouraged to discuss the proposed budgets with NCI Program Staff. Engineering and Physical Sciences
According to the current listing, eligibility includes: Small Business Concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any federal agency for cancer-relevant technologies. Confirm the full requirements in the official notice before applying.
The current listing shows not specified (Phase II awards typically up to $2,000,000 for NCI SBIR/STTR). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was August 21, 2024, which has passed. Check the official notice for any future application windows before investing time in a proposal.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article